Loading...
Loading...
CEL-SCI Corporation
CVM today announced that in March it has
enrolled 29 patients with advanced primary, not yet treated, head and neck
cancer into its global pivotal Phase III head and neck cancer trial for its
investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection).
March marks the third consecutive month of record enrollment for CEL-SCI this
year following January and February 2015. 406 patients have been enrolled in
the Phase III study as of March 31, 2015.
"The accelerating pace of enrollment in our trial is very good. We expect to
see continued increases in monthly patient enrollment throughout the year as
new clinical centers are added and as existing centers gain more experience
with Multikine," stated CEL-SCI Chief Executive Officer Geert Kersten.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in